API Holdings' Siddharth Shah on what’s next for Thyrocare after the PharmEasy deal, API’s existing online drug delivery business, and what he makes of deep-pocketed rivals Reliance and Tata Group. Excerpts from the interview:
from Tech-Economic Times
via IFTTT
No comments:
Post a Comment